[L-dopa/benserazide during pregnancy in a patient with juvenile parkinsonism].

Abstract

We report a 34-year-old woman with juvenile parkinsonism who had been treated with five tablets daily of l-dopa/benserazide (100 mg/25 mg). She became pregnant in May 1995 and continued the same treatment. She delivered a healthy boy (3,798 g, 52 cm) with Apgar scores of 9 at 38 weeks gestation by normal delivery. In animal study, there is a report of teratogenicity (bone abnormality) of l-dopa/benserazide in rabbits at doses of 30 mg/kg and 120 mg/kg. However, there have been several reports of uneventful delivery of normal children in patients with juvenile parkinsonism who had been treated with l-dopa/decarboxylase inhibitor (DCI) during pregnancy. There seems to be no firm reason to avoid pregnancy during the treatment of l-dopa/DCI or to withhold l-dopa/DCI during pregnancy.

• Authors: H Arai, H Shinotoh, T Hattori
• Journal: Rinsho shinkeigaku = Clinical neurology (Rinsho Shinkeigaku) Vol. 37 Issue 3 Pg. 264-5 (Mar 1997) ISSN: 0009-918X [Print] Japan
• PMID: 9217430 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antiparkinson Agents
• Carbonic Anhydrase Inhibitors
• Levodopa
• Benserazide

Topics

• Adult
• Animals
• Antiparkinson Agents (administration & dosage)
• Benserazide (administration & dosage)
• Carbonic Anhydrase Inhibitors (administration & dosage)
• Drug Therapy, Combination
• Female
• Humans
• Infant, Newborn
• Levodopa (administration & dosage)
• Male
• Parkinson Disease (drug therapy)
• Pregnancy
• Pregnancy Complications (drug therapy)
• Rabbits